Early data show Bicara’s bispecific helps shrink head and neck cancers when combined with Keytruda: #ASCO23 June 5, 2023
Bicara Therapeutics’ First-in-class Bifunctional EGFR/TGF-β Inhibitor, BCA101, Demonstrates 65% ORR in Combination with Pembrolizumab in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) June 5, 2023
WelbeHealth Continues Los Angeles Expansion With Opening of New PACE Centers in Rosemead and North Hollywood June 1, 2023